尽管已经完成了几项研究来调查细胞减灭手术（CRS）联合或不联合腹腔热灌注化疗（HIPEC）对子宫内膜癌腹膜转移（ECPM）的影响，但之前尚未进行直接比较。进行了一项荟萃分析，以调查 CRS 联合 HIPEC 相对于仅 CRS 的疑似额外生存益处。分别确定了 21 项和 10 项研究，总共 1116 例和 152 例仅调查 CRS 和 CRS 加 HIPEC 的病例。对所有文章进行分析后，CRS 加 HIPEC 的 1 年生存率高出 17.60%（82.28% vs. 64.68%；p = 0.0102）。 2 年观察到相同的趋势（56.07% vs. 36.95%；差异：19.12%；p = 0.0014），但 5 年则不然（21.88% vs. 16.45%；差异：5.43%；p = 0.3918) 存活率。如果仅对 2010 年之后发表的研究进行调查，则可以得出相同的临床意义，但统计学上不太强的观察结果（1 年生存率：12.08% 和 p = 0.0648；2 年生存率：10.90% 和 p = 0.0988） 。 CRS 仍然是 ECPM 治疗的核心要素之一，但在 CRS 中添加 HIPEC 可以增加积极的临床结果，尤其是在前 2 年。

Although several studies have been completed to investigate the effect of cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in endometrial cancer with peritoneal metastasis (ECPM), a direct comparison was not performed previously. A meta-analysis was performed to investigate the suspected additional survival benefits of CRS plus HIPEC over CRS only. Twenty-one and ten studies with a total number of 1116 and 152 cases investigating CRS only and CRS plus HIPEC were identified, respectively. When all articles were analyzed, the 1-year survival rate was 17.60% higher for CRS plus HIPEC (82.28% vs. 64.68%; p = 0.0102). The same tendency was observed for the 2-year (56.07% vs. 36.95%; difference: 19.12%; p = 0.0014), but not for the 5-year (21.88% vs. 16.45%; difference: 5.43%; p = 0.3918) survival rates. The same clinical significance, but statistically less strong observations, could be made if only the studies published after 2010 were investigated (1-year survival rate: 12.08% and p = 0.0648; 2-year survival rate: 10.90% and p = 0.0988). CRS remains one of the core elements of ECPM treatment, but the addition of HIPEC to CRS can increase the positive clinical outcome, especially in the first 2 years.